566 related articles for article (PubMed ID: 17149362)
1. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
2. FUP1, a gene associated with hepatocellular carcinoma, stimulates NIH3T3 cell proliferation and tumor formation in nude mice.
Pan W; Zhang Q; Xi QS; Gan RB; Li TP
Biochem Biophys Res Commun; 2001 Sep; 286(5):1033-8. PubMed ID: 11527404
[TBL] [Abstract][Full Text] [Related]
3. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice.
Sun Y; Lin R; Dai J; Jin D; Wang SQ
Oligonucleotides; 2006; 16(4):365-74. PubMed ID: 17155911
[TBL] [Abstract][Full Text] [Related]
4. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
Kunze D; Wuttig D; Kausch I; Blietz C; Blumhoff L; Burmeister Y; Kraemer K; Fuessel S; Toma M; Schwenzer B; Meye A; Grimm MO; Hakenberg OW; Jocham D; Wirth MP
Int J Oncol; 2008 May; 32(5):1049-56. PubMed ID: 18425331
[TBL] [Abstract][Full Text] [Related]
5. Control of complexity constraints on combinatorial screening for preferred oligonucleotide hybridization sites on structured RNA.
Bruice TW; Lima WF
Biochemistry; 1997 Apr; 36(16):5004-19. PubMed ID: 9125523
[TBL] [Abstract][Full Text] [Related]
6. Antisense radiotherapy: targeting full-size mdrl mRNA with 125I-labelled oligonucleotides.
Gaidamakova EK; Neumann RD; Panyutin IG
Int J Radiat Biol; 2004; 80(11-12):889-93. PubMed ID: 15764398
[TBL] [Abstract][Full Text] [Related]
7. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
Weidner DA; Busch H
Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
[TBL] [Abstract][Full Text] [Related]
8. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells.
Kim Y; Yoon JW; Xiao X; Dean NM; Monia BP; Marcusson EG
Cancer Res; 2007 Apr; 67(8):3583-93. PubMed ID: 17440069
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA.
Clawson GA; Miranda GQ; Sivarajah A; Xin P; Pan W; Thiboutot D; Christensen ND
Gene Ther; 2004 Sep; 11(17):1331-41. PubMed ID: 15229628
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
Sieghart W; Losert D; Strommer S; Cejka D; Schmid K; Rasoul-Rockenschaub S; Bodingbauer M; Crevenna R; Monia BP; Peck-Radosavljevic M; Wacheck V
J Hepatol; 2006 Jan; 44(1):151-7. PubMed ID: 16289418
[TBL] [Abstract][Full Text] [Related]
11. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
12. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer.
Cao C; Mu Y; Hallahan DE; Lu B
Oncogene; 2004 Sep; 23(42):7047-52. PubMed ID: 15258565
[TBL] [Abstract][Full Text] [Related]
13. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
[TBL] [Abstract][Full Text] [Related]
14. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells.
Choi KS; Lee TH; Jung MH
Cancer Gene Ther; 2003 Feb; 10(2):87-95. PubMed ID: 12536196
[TBL] [Abstract][Full Text] [Related]
15. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
[TBL] [Abstract][Full Text] [Related]
16. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
Sapra P; Wang M; Bandaru R; Zhao H; Greenberger LM; Horak ID
Nucleosides Nucleotides Nucleic Acids; 2010 Feb; 29(2):97-112. PubMed ID: 20391197
[TBL] [Abstract][Full Text] [Related]
17. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
[TBL] [Abstract][Full Text] [Related]
18. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
Klasa RJ; Bally MB; Ng R; Goldie JH; Gascoyne RD; Wong FM
Clin Cancer Res; 2000 Jun; 6(6):2492-500. PubMed ID: 10873104
[TBL] [Abstract][Full Text] [Related]
19. Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer.
Tong QS; Zheng LD; Chen FM; Zeng FQ; Wang L; Dong JH; Lu GC
World J Gastroenterol; 2005 Feb; 11(5):634-40. PubMed ID: 15655812
[TBL] [Abstract][Full Text] [Related]
20. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
